Online consultations available nationwide, with home delivery across Japan.
International patients are very welcome. Customs certificates for returning travelers are also available.
- We use GLP-1 medications daily in our diabetes practice, giving us thorough knowledge of the drug’s properties, effects, and risks
- Comprehensive management of side effects (nausea, gastrointestinal symptoms). As internists, we can prescribe anti-nausea medication and additional treatments as needed
- 血糖、血压、血脂等生活习惯病指标一并管理
- 睡眠呼吸暂停（肥胖的常见并发症）也在本院接受治疗
- We provide 在全面考虑健康的同时支持减重, not just aesthetics
What Is Wegovy?
Wegovy (generic name: semaglutide 2.4mg) is a GLP-1 receptor agonist officially approved in Japan for obesity treatment in 2023. With once-weekly subcutaneous injections, the STEP 1 clinical trial (1,961 participants, 68 weeks) confirmed an average weight reduction of approximately 14.9%.
It acts directly on the brain’s satiety center to suppress appetite, physiologically creating a state where you feel less hungry and are satisfied with smaller portions — supporting weight loss without relying on willpower or strict dieting.
适合哪些人？
- Those seeking significant weight loss (10 kg or more)
- Those for whom other GLP-1 medications (Rybelsus, Ozempic, etc.) were insufficiently effective
- Those with BMI ≥ 27 with comorbidities such as hypertension, diabetes, or dyslipidemia
- Those with BMI ≥ 35
- Those who want to minimize effort with a once-weekly injection
- Those who have repeatedly tried conventional diets without achieving lasting results
哪些人不能使用？
- Those with a history of pancreatitis
- Those with a personal or family history of medullary thyroid carcinoma or MEN2
- 正在怀孕、计划怀孕或哺乳的人
- BMI低于18.5的人
- Those with severe gastrointestinal disorders
常见副作用
The most common side effects are gastrointestinal symptoms such as nausea, diarrhea, and constipation. Most resolve within 2–4 weeks after starting treatment. We can prescribe anti-nausea medication if needed.
| 副作用 | 频率 | 处理方法 |
|---|---|---|
| 恶心 | ~20–30% | 少量多次进食；止吐药 |
| 腹泻 | ~10–20% | 补充水分；整肠药 |
| 便秘 | ~10–20% | 补充水分、膳食纤维、泻药 |
| 头痛 / 疲劳 | ~5–10% | 观察 |
| 急性胰腺炎（罕见） | <0.1% | 出现严重上腹/背部疼痛时立即就医 |
费用（含税，运费另计）
运费：¥35,000以上免费 / ¥35,000以下¥1,500 / 不可退货 / 付款：信用卡、银行转账或现金
就诊流程
💊 问诊费用
¥0 — 您已明确所需药物及剂量
¥5,500 — 您希望就药物选择、剂量或减重方案进行咨询 （日语或英语）
🏥 来院就诊（北海道札幌市中央区）
🖥 线上问诊（全国对应）
-
预约
点击此处进行预约。
完成后，我们将通过电子邮件发送诊疗用URL。
※ 如未收到邮件，请检查垃圾邮件文件夹。 -
线上诊疗
无需安装任何应用程序！点击邮件中的URL即可。
将通过视频通话进行本人确认。（※ 依据日本厚生劳动省远程医疗指南）
请准备好附有照片的身份证明文件。 -
付款
仅限信用卡 -
配送
线上诊疗结束后进行结算，发货至您指定的地址。
可发往住宅、公司或酒店等全国各地。不支持海外发货。
※ 可为归国旅客开具海关证明。※ 不支持国际配送。
常见问题
- Q. 接受健康保险吗？
- 在没有糖尿病诊断的情况下用于减重时，治疗为自费（私人）。 已诊断为糖尿病的患者可能有资格享受保险覆盖。
- Q. How much weight can I expect to lose?
- In the STEP 1 clinical trial, an average of approximately 14.9% weight loss was confirmed. For a person weighing 80 kg, that equates to approximately 12 kg. Individual results may vary.
- Q. How does Wegovy compare to Mounjaro?
- Mounjaro (tirzepatide), with its dual GLP-1/GIP action, has shown greater weight reduction (avg. over 20%) than Wegovy. If you are looking for stronger weight loss, Mounjaro may be the better choice.
- Q. 停药后会反弹吗？
- 停药后食欲可能恢复，有可能体重反弹。在治疗期间养成健康饮食习惯是防止反弹的关键。
- Q. 外国患者可以接受治疗吗？
- 是的，可提供英语服务。我们还可以在您返回本国时为您出具海关申报所需的诊断证明书。
- Q. Wegovy（司美格鲁肽）有哪些副作用？
- 常见副作用包括：恶心、腹泻、便秘、呕吐、腹痛、疲劳、头痛、头晕、注射部位反应、急性胰腺炎、肠梗阻、胆道疾病、低血糖、急性肾损伤等。
- Q. 在线诊疗后，药品何时送达？
- 付款在线上诊疗期间完成。药品将于发货日后第二天送达（全国配送，北海道至冲绳）。
发货日因就诊时间而异。
以下情况可能导致延迟：就诊时间 发货日 周一・周二・周四・周五 11:30前 当天发货 其他（11:30后・周三・周六・休诊日） 次诊疗日发货
・批发商库存不足时
・台风・暴雪等恶劣天气导致的配送延误
预约线上或来院诊疗
预约 / 申请[Physician Explanation] Wegovy (Semaglutide): Effects, 副作用s, and STEP Trial Data